SciELO - Scientific Electronic Library Online

 
vol.107 suppl.1Cutaneous lesions sensory impairment recovery and nerve regeneration in leprosy patientsIdentification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Memórias do Instituto Oswaldo Cruz

versão impressa ISSN 0074-0276

Resumo

GONCALVES, Heitor de Sá et al. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects. Mem. Inst. Oswaldo Cruz [online]. 2012, vol.107, suppl.1, pp.74-78. ISSN 0074-0276.  http://dx.doi.org/10.1590/S0074-02762012000900013.

This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.

Palavras-chave : leprosy; multibacillary leprosy; paucibacillary leprosy; adverse effects; therapeutics; leprostatic agents.

        · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons